Skip to main content

Table 2 HBV, HCV and HDV infection in HCC patients and controls and estimates of HCC risk

From: A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa

Hepatitis markers Controls HCC cases Unadjusted HCC risk Adjusted HCC risks
  No % No % OR (95 % CI) OR (95 % CI)
HBV status
 HBsAg positive 9 10.6 58 65.9 16.3 7.2-37.1 141.7 11.5-1747.6
 HBeAg positive 1 11.1 5 8.6 11.2 0.6-207.3 38.79 4.04-305.2
 Anti-HBc positive 67 78.8 73 82.9 1.31 0.6-28 0.68 0.03-16.7
 Anti-HBs positive 59 69.4 23 26.1 0.16 0.8-3.2 0.56 0.018-15.1
HCV status
 Anti-HCV positive 3 3.5 23 26.1 9.7 2.7-33.6 51.9 3.8-711.03
HDV status
 Anti-HDV positive HBV-related 1 11.1 24 41.1 5.72 0.75-39.27. 5.65 0.66-48.16
 Anti-HDV positive 1 1.17 24 27.27 29.3 4.1-1231 35.65 3.66-682.16
  1. Note: Adjusted analysis represents multivariable model including age gender. Abbreviations: HCC hepatocellular carcinoma, HBV hepatitis B virus, HCV hepatitis C virus, HBsAg hepatitis B surface antigen, Anti-HBc antibody against hepatitis B core antigen, Anti-HBs antibody against hepatitis B surface antigen, Anti-HCV antibody against hepatitis C virus, Anti-HDV antibody against hepatitis D virus, CI Confidence intervals, OR Odds Ratio